CoChat

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Haessler, Jeffrey, Shaughnessy, John D., Zhan, Fenghuang, Crowley, John, Epstein, Joshua, van Rhee, Frits, Anaissie, Elias, Pineda-Roman, Mauricio, Zangari, Maurizio, Hollmig, Klaus, Mohiuddin, Abid, Alsayed, Yazan, Hoering, Antje, Tricot, Guido, Barlogie, Bart · 2007 · Clinical Cancer Research
Cited by 101

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Experimental Design: To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma. Patients and Methods: Newly diagnosed patients with myeloma received a tandem autotransplant regimen. Using multivariate regression analyses, we examined the prognostic implications of time-dependent onset of CR on overall survival and event-free survival in the context of standard prognostic factors (SPF) and gene expression profiling–derived data available for 326 patients. Results: CR benefited patients regardless of risk status when only SPFs were examined. With knowledge of gene array data, a survival (and event-free survival) benefit of CR only pertained to the small high-risk subgroup of 13% of patients (hazard ratio, 0.23; P = 0.001), whereas the majority of patients with low-risk disease had similar survival expectations whether or not CR was achieved (hazard ratio, 0.68; P = 0.128). Conclusions: Access to gene expression information permitted the recognition of a small very high-risk subgroup of 13% of patients, in whom prolonged survival critically depended on achieving CR. Absence of such benefit in the remainder should lead to a reassessment of clinical trial designs that rely on this end point as a surrogate for long-term prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-0527

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 101

Metadata

Authors
Haessler, J., Shaughnessy, J. D., Zhan, F., Crowley, J., Epstein, J., van Rhee, F., Anaissie, E., Pineda-Roman, M., Zangari, M., Hollmig, K., Mohiuddin, A., Alsayed, Y., Hoering, A., Tricot, G., & Barlogie, B.
Venue
Clinical Cancer Research
Published
2007-12-01
Volume
13
Issue
23
Pages
7073-7079
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2135326558
Cited by
101
References
2
FWCI
7.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0527
The paper
Haessler, J., Shaughnessy, J. D., Zhan, F., Crowley, J., Epstein, J., van Rhee, F., Anaissie, E., Pineda-Roman, M., Zangari, M., Hollmig, K., Mohiuddin, A., Alsayed, Y., Hoering, A., Tricot, G., & Barlogie, B. (2007). Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0527

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.